Brokerages expect that Allogene Therapeutics, Inc. (NASDAQ:ALLO) will announce sales of $24.50 million for the current fiscal quarter, according to Zacks. Two analysts have provided estimates for Allogene Therapeutics’ earnings. The lowest sales estimate is $10.00 million and the highest is $38.99 million. The business is expected to announce its next earnings results after the market closes on Wednesday, May 5th.

According to Zacks, analysts expect that Allogene Therapeutics will report full-year sales of $39.50 million for the current financial year, with estimates ranging from $38.99 million to $40.00 million. For the next financial year, analysts expect that the firm will report sales of $0.00. Zacks’ sales averages are an average based on a survey of sell-side analysts that that provide coverage for Allogene Therapeutics.

Allogene Therapeutics (NASDAQ:ALLO) last released its quarterly earnings data on Wednesday, February 24th. The company reported ($0.53) EPS for the quarter, topping the consensus estimate of ($0.56) by $0.03.

A number of equities research analysts recently weighed in on the stock. HC Wainwright reaffirmed a “buy” rating on shares of Allogene Therapeutics in a report on Thursday, April 22nd. Stifel Nicolaus upgraded shares of Allogene Therapeutics from a “hold” rating to a “buy” rating and raised their price target for the stock from $33.00 to $43.00 in a research report on Tuesday, January 26th. Zacks Investment Research upgraded shares of Allogene Therapeutics from a “hold” rating to a “buy” rating and set a $35.00 price objective on the stock in a research report on Thursday, February 11th. Finally, Oppenheimer reiterated a “buy” rating on shares of Allogene Therapeutics in a research report on Monday, April 12th. Three analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company’s stock. Allogene Therapeutics has a consensus rating of “Buy” and a consensus price target of $50.77.

In related news, General Counsel Veer Bhavnagri sold 10,000 shares of the stock in a transaction dated Thursday, April 15th. The shares were sold at an average price of $32.05, for a total transaction of $320,500.00. Following the completion of the transaction, the general counsel now directly owns 431,353 shares of the company’s stock, valued at $13,824,863.65. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 31.30% of the stock is owned by insiders.

Several institutional investors and hedge funds have recently made changes to their positions in ALLO. Credit Suisse AG lifted its position in Allogene Therapeutics by 13.6% in the 4th quarter. Credit Suisse AG now owns 132,164 shares of the company’s stock valued at $3,336,000 after purchasing an additional 15,797 shares during the last quarter. Primecap Management Co. CA acquired a new position in Allogene Therapeutics during the 4th quarter valued at $31,257,000. Sowell Financial Services LLC acquired a new position in Allogene Therapeutics during the 4th quarter valued at $93,000. California Public Employees Retirement System increased its holdings in Allogene Therapeutics by 4.2% in the 4th quarter. California Public Employees Retirement System now owns 116,646 shares of the company’s stock valued at $2,944,000 after buying an additional 4,746 shares during the period. Finally, DekaBank Deutsche Girozentrale increased its holdings in Allogene Therapeutics by 11.4% in the 4th quarter. DekaBank Deutsche Girozentrale now owns 45,900 shares of the company’s stock valued at $1,237,000 after buying an additional 4,700 shares during the period. 59.86% of the stock is currently owned by institutional investors and hedge funds.

Shares of ALLO stock opened at $30.65 on Friday. The company has a market cap of $4.34 billion, a PE ratio of -14.39 and a beta of 1.28. Allogene Therapeutics has a 52 week low of $24.85 and a 52 week high of $55.00. The company’s fifty day simple moving average is $34.17 and its 200-day simple moving average is $32.53.

About Allogene Therapeutics

Allogene Therapeutics, Inc, a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell ALL.

Featured Story: Google Finance Portfolio

Get a free copy of the Zacks research report on Allogene Therapeutics (ALLO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Allogene Therapeutics (NASDAQ:ALLO)

Receive News & Ratings for Allogene Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allogene Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.